diazomethane has been researched along with Alzheimer Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chao, H; Ding, W; Kuang, S; Kumar, M; Liang, SH; Mondal, P; Ran, C; Shen, S; Tanzi, RE; Wu, B; Yang, F; Yang, L; Zhang, C; Zhang, J; Zhu, B | 1 |
| Arai, T; Araya, T; Kanai, M; Kino, R; Sohma, Y | 1 |
| Bahr, BA; Bowers, MT; Gessel, MM; Viswanathan, K; Wisniewski, ML; Wright, DL; Zheng, X | 1 |
| Bahr, BA; Butler, D; Wisniewski, ML | 1 |
| Bahr, BA; Bendiske, J | 1 |
| Bi, X; Lynch, G; Zhou, J | 1 |
| Bi, X; Ellman, JA; Haque, TS; Kuntz, ID; Lee, CE; Lin, B; Lynch, G; Skillman, AG; Zhou, J | 1 |
7 other study(ies) available for diazomethane and Alzheimer Disease
| Article | Year |
|---|---|
A Photolabile Curcumin-Diazirine Analogue Enables Phototherapy with Physically and Molecularly Produced Light for Alzheimer's Disease Treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Curcumin; Diazomethane; Disease Models, Animal; Mice; Mice, Transgenic; Phototherapy | 2023 |
Covalent modifier-type aggregation inhibitor of amyloid-β based on a cyclo-KLVFF motif.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line; Diazomethane; Humans; Peptide Fragments; Peptides, Cyclic; Protein Aggregates; Protein Aggregation, Pathological; Rats | 2015 |
Z-Phe-Ala-diazomethylketone (PADK) disrupts and remodels early oligomer states of the Alzheimer disease Aβ42 protein.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloidosis; Animals; Diazomethane; Dimerization; Disease Models, Animal; Drug Design; Humans; Mass Spectrometry; Mice; Microscopy, Electron; Peptide Fragments; Protein Folding; Protein Structure, Secondary; Solubility | 2012 |
Positive lysosomal modulation as a unique strategy to treat age-related protein accumulation diseases.
Topics: Aging; alpha-Synuclein; Alzheimer Disease; Animals; Cathepsins; Dementia; Diazomethane; Humans; Huntingtin Protein; Huntington Disease; Ketones; Lysosomes; Mice; Mice, Transgenic; Nerve Tissue Proteins; Nuclear Proteins; Phagocytosis; Protease Inhibitors; Proteins; rab GTP-Binding Proteins; Synapses; tau Proteins | 2012 |
Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis--an approach for slowing Alzheimer disease?
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cathepsins; Chloroquine; Culture Techniques; Cysteine Proteinase Inhibitors; Diazomethane; Disease Models, Animal; Enzyme Activation; Hippocampus; Hydrolases; Lysosomes; Rats; Rats, Sprague-Dawley; Synapses; tau Proteins | 2003 |
Lysosomal protease inhibitors induce meganeurites and tangle-like structures in entorhinohippocampal regions vulnerable to Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Cathepsin B; Cathepsin L; Cathepsins; Chloroquine; Cysteine Endopeptidases; Diazomethane; Endopeptidases; Entorhinal Cortex; Hippocampus; Humans; Lysosomes; Neurites; Neurofibrillary Tangles; Organ Culture Techniques; Rats; Rats, Sprague-Dawley; Serine Proteinase Inhibitors | 1999 |
Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus.
Topics: Alzheimer Disease; Animals; Cathepsin D; Diazomethane; Dose-Response Relationship, Drug; Enzyme Inhibitors; Excitatory Postsynaptic Potentials; Hippocampus; Lysosomes; Organ Culture Techniques; Peptide Fragments; Phosphoproteins; Phosphorylation; Rats; Rats, Sprague-Dawley; tau Proteins | 2000 |